![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BioNTech, Fosun Pharma Vaccinate Patients in New Phase 1 Chinese Study
BioNTech, Fosun Pharma Vaccinate Patients in New Phase 1 Chinese Study
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/China_Map.gif?t=1478215210&width=430)
Germany-based BioNTech and Fosun Pharma have begun a phase 1 trial of their COVID-19 vaccine candidate in China.
The trial will include a total of 144 patients, who will either receive two 10-microgram or 30-microgram doses of the messenger RNA-based vaccine candidate BNT162b1 or a placebo.
BioNTech is supplying the vaccine for the China trial from its manufacturing facilities in Europe.
Upcoming Events
-
21Oct